UMN Pharma Inc. announced consolidated earnings results for the first nine months ended September 30, 2015. For the period, the company reported net sales of JPY 70 million against JPY 1,094 million a year ago. Operating loss was JPY 2,959 million against JPY 2,979 million a year ago. Ordinary loss was JPY 3,075 million against JPY 3,226 million a year ago. Net loss was JPY 3,074 million against JPY 2,937 million a year ago. Net loss per share was JPY 321.28 against JPY 345.78 a year ago. Loss before income taxes and minority interests was JPY 3,075,559,000 against JPY 2,979,458,000 a year ago. Net cash used in operating activities was JPY 2,884,899,000 against JPY 1,085,337,000 a year ago, mainly due to loss before income taxes of JPY 3,075,559,000. Purchase of property, plant and equipment was JPY 254,752,000 against JPY 4,160,000 a year ago. Purchase of intangible assets was JPY 2,600,000 against JPY 3,306,000 a year ago.

The company provided consolidated earnings guidance for the year ending March 31, 2016. For the year, the company expects net sales of JPY 222 million, operating loss of JPY 3,224 million, ordinary loss of JPY 3,404 million, net loss of JPY 3,405 million and net loss per share of JPY 355.87. The company previously expected net sales of JPY 2,254 million, operating loss of JPY 1,697 million, ordinary loss of JPY 1,844 million, net loss of JPY 1,852 million and net loss per share of JPY 193.54.